98%
921
2 minutes
20
Implantable cardiovascular devices have revolutionized the management of cardiovascular diseases, significantly enhancing patients' quality of life. With the increasing demand of cardiac implantable electronic devices, the imperative for novel device development is evident. This review article first elaborates the mechanisms underlying foreign body response and infection, elucidating the complex interplay between implanted constructs and host tissues. The discussion then focuses on current advancements in materials science and engineering aimed at mitigating these challenges. Material innovations, such as drug-eluting materials, surface modifications, and biomimetic materials, are explored as strategies to modulate these responses and to prevent fibrotic or thrombotic complications and infection. Finally, future directions in materials development for implantable cardiovascular devices are introduced. By addressing safety and patency concerns through innovative material strategies, this article aims to guide the research and development of advanced materials for both current and future cardiovascular implantable devices, ultimately improving patient outcomes and advancing cardiovascular disease treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162047 | PMC |
http://dx.doi.org/10.1007/s12274-024-6808-x | DOI Listing |
Eur Heart J Case Rep
September 2025
Feinberg School of Medicine, Northwestern University, 303E Chicago Ave, Ward 1-003, Chicago, IL 60611, USA.
Background: Cardiac laminopathies, associated with mutations in the LMNA gene, are a rare inherited disorder characterized by a broad range of clinical manifestations. There are currently no data on the association between supraventricular re-entrant tachycardias and LMNA-related cardiomyopathy.
Case Summary: A 26-year-old male presented with either wide-QRS tachycardia with a left bundle branch block (LBBB) pattern or narrow QRS tachycardia, as well as a history of palpitations since age 15.
Eur Heart J Case Rep
September 2025
Department of Cardiology, Toyohashi Heart Center, 21-1 Gobutori, Oyamacho, Toyohashi 441-8530, Japan.
Background: Mitral regurgitation (MR) may rarely worsen after transcatheter aortic valve implantation (TAVI) due to mechanical interference from the transcatheter heart valve (THV). Standard surgical approaches in these cases are often challenging due to anatomical constraints. Thus, there is a need for the development of effective alternatives to address this issue.
View Article and Find Full Text PDFRev Cardiovasc Med
August 2025
Department of Cardiology, Harbin Medical University, 150000 Harbin, Heilongjiang, China.
Background: Differences between female and male patients may influence the outcomes of transcatheter aortic valve replacement (TAVR). However, knowledge regarding known sex differences in TAVR procedures among Chinese people remains limited. Therefore, this study aimed to investigate the impact of sex-related differences on reverse left ventricular (LV) remodeling following TAVR in the Chinese population.
View Article and Find Full Text PDFRev Cardiovasc Med
August 2025
E. Meshalkin National Medical Research Center, Institute of Cardiovascular Pathology Research, 630055 Novosibirsk, Russian Federation.
Background: Presently, the availability of single-stage surgical correction of mitral valve disease combined with atrial fibrillation (AF) via a mini-access approach remains limited. Moreover, the comparative effectiveness of this procedure versus conventional sternotomy (CS) remains poorly understood. Thus, this study aimed to conduct a comparative assessment of the efficacy and safety of concomitant mitral valve surgery and AF ablation via a minimally invasive approach (minimally invasive cardiac surgery, MICS group) versus the standard sternotomy approach (CS group).
View Article and Find Full Text PDFCatheter Cardiovasc Interv
September 2025
Department of Cardiology, Barts Heart Center, Barts Health NHS Trust, London, UK.
Background: Degeneration of surgical bioprosthetic aortic valves is increasingly common. Redo surgical aortic valve replacement carries substantial morbidity and mortality, particularly in elderly or high-risk patients. Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) has become an established alternative, though data on the performance of self-expanding Portico and Navitor valves remain limited.
View Article and Find Full Text PDF